Login to Your Account



NeuroSearch, GSK Try Again, Enter $27M Deal On Depression

By Cormac Sheridan


Tuesday, November 26, 2002
GlaxoSmithKline plc has taken that old adage to heart. Undeterred by the previous failure in Phase II trials of a candidate antidepressant it had licensed from the Danish firm NeuroSearch A/S, it has returned to the well in search of a fresh source of triple-action compounds that block reuptake of the neurotransmitters dopamine, noradrenaline and serotonin. (Bioworld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription